BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910
BI-1910 is now the second of the company’s anti-tumour necrosis factor receptor 2 programmes to enter clinical development
Read More
Author: Jen Brogan
NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks
The final draft guidance recommends rimegepant for adults who have at least four migraine attacks per month, but less than 15
Read More
FDA approves ANDA of 20mg generic Nitisinone capsules
Nitisinone capsules are indicated for patients with hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine
Read More
Lonza to acquire Synaffix to strengthen ADC development
Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services
Read More
Sanofi announces positive data for frexalimab in relapsing MS
The neurological disease affects approximately 2.8 million people worldwide
Read More- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
